Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus
JAMA Dermatology · 2023
DOI: 10.1001/jamadermatol.2023.0175 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Katharina Shaw und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This case series examines the efficacy of anifrolumab as a therapeutic option for patients with lupus erythematosus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Division of Dermatology, University of Vermont Medical Center, Burlington.
Zitieren
APA
Shaw, K., Sanchez-Melendez, S., Taylor, D., Barker, J., LaChance, A., Shahriari, N., & Vleugels, R. A. (2023). Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2023.0175
Vancouver
Shaw K, Sanchez-Melendez S, Taylor D, Barker J, LaChance A, Shahriari N, et al. Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2023.0175
BibTeX
@article{Shaw2023,
author = {Shaw, Katharina and Sanchez-Melendez, Stephanie and Taylor, Dustin and Barker, Julia and LaChance, Avery and Shahriari, Neda and Vleugels, Ruth Ann},
title = {Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus},
journal = {JAMA Dermatology},
year = {2023},
doi = {10.1001/jamadermatol.2023.0175}
}
EUVIMED